Mithridion, Inc. develops drugs for serious chronic neurodegenerative and orphan diseases. The Company manufactures small molecule drugs to address major unmet medical needs such as to improve memory and cognition, stop the disease processes for which no effective drug exists, and neuron loss. Mithridion shut down in June 2013.
